Russian scientists of three RAS institutes: molecular genetics, bio-organic chemistry and biology of the gene created a gene therapy drug that is effective and safe for the patient in struggling with some types of cancer. In particular, the drug destroys the cells of head and neck cancer, colon and cervical cancer.
The product consists of two components - modified killer gene of herpes simplex virus thymidine kinase (HSVtk) and an immune stimulant GM-CSF. Treatment goes in two stages. First, the drug AntionkoRAN-M is introduced into the tumor. Further, non-toxic prodrug, intravenously inserted into an organism, interacts with the drug and converts into a toxin that kills the cancer cells. These toxins also penetrate into the neighboring cancerous cells, which increases the effect of the drug, and effect on metastasis.
Currently, scientists completed pre-clinical trials of the drug on the basis of the oncology institute n.a Herzen. According to their results, life expectancy grows at 72-86%, tumor growth less at 75-83%, 80-85% less growth of metastasis (depending on the type of tumors) and the drug is safe for the patient.
In 2014 AntionkoRAN-M entered the list of the most important achievements of the Russian Academy of Sciences. In 2015 it became one of the finalists Generation S startup accelerator. For the drug roll-out on the market, it is necessary to conduct clinical trials, patenting, licensing, manufacturing and marketing of drugs on the market, what requires additional investments.